Often searched with CJC-1295 in GH secretagogue research.
Part of the Growth hormone & IGF peptides cluster
Overview
Ipamorelin is a selective growth hormone secretagogue receptor agonist peptide studied for GH release with a relatively focused receptor profile compared with earlier GHRPs.
Source & context
Biological / chemical source: Synthetic pentapeptide
Primary research or clinical context: Research compound (not an approved drug)
Receptor selectivity
Ipamorelin is frequently described as more selective than GHRP-2 or GHRP-6, with less reported impact on cortisol and prolactin in experimental contexts — a key reason for its research popularity.
FAQ about Ipamorelin
What is Ipamorelin?+
Ipamorelin is a selective growth hormone secretagogue receptor agonist peptide studied for GH release with a relatively focused receptor profile compared with earlier GHRPs.
Is Ipamorelin an approved medicine?+
Ipamorelin is discussed here as a research / educational topic. Research compound (not an approved drug). This is not medical advice.
What is the typical length of Ipamorelin?+
Ipamorelin is commonly described as approximately 5 amino acids (Research peptide).
Related peptides
References & further reading
- 1.Wikipedia — Ipamorelin
- 2.PubChem — compound summary for Ipamorelin (CID 9831659)
- 3.Raun et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol
- 4.Johansen et al. (1999). Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res
- 5.Malmlöf et al. (1999). Methylprednisolone does not inhibit the release of growth hormone after intravenous injection of a novel growth hormone secretagogue in rats. Growth Horm IGF Res
- 6.Svensson et al. (2000). The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol
- 7.Andersen et al. (2001). The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Horm IGF Res
- 8.Venkova et al. (2009). Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. J Pharmacol Exp Ther
- 9.Greenwood-Van Meerveld et al. (2012). Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. J Exp Pharmacol
- 10.Beck et al. (2014). Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis
- 11.Broglio et al. (2002). Ghrelin: much more than a natural growth hormone secretagogue. Isr Med Assoc J
- 12.Halem et al. (2004). Novel analogs of ghrelin: physiological and clinical implications. Eur J Endocrinol
- 13.Fehrentz et al. (2002). Growth hormone secretagogues: past, present and future. IDrugs
- 14.Smith et al. (1993). A nonpeptidyl growth hormone secretagogue. Science
- 15.Kojima et al. (1999). Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature
- 16.Shin et al. (2015). Therapeutic applications of ghrelin agonists in the treatment of gastroparesis. Curr Gastroenterol Rep
- 17.Greenwood-Van Meerveld et al. (2011). Ghrelin as a target for gastrointestinal motility disorders. Peptides